ArticleCardiovascular & hematological disorders drug targets2022
Antihypertensive and Vasorelaxant Effects of
Article in Cardiovascular & hematological disorders drug targets, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
- Preliminary Characterization of the Vasorelaxant Effect ofCurrent drug discovery technologies · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
aimsThe aim of the study was to assess the antihypertensive activity of Rumex vesicarius.
backgroundThe genus Rumex (sorrel, Polygonaceae), containing approximately 200 species, is distributed worldwide (African, European, Asian, and American countries). It is widely used in traditional medicine as analgesic, diuretic, antispasmodic, and antihypertensive plant.
objectivesThis study aimed to assess the possible antihypertensive vasorelaxant capacity and effect on angiotensin-converting enzyme 2 (ACE-2) of the aqueous extract of Rumex vesicarius (R. vesicarius).
methodsIn the present study, the aqueous extract of R. vesicarius (AERV) was prepared, its antihypertensive activity was examined in N(ω)-nitro-L-arginine methyl ester(L-NAME)-induced hypertensive rats, and its vasorelaxant ability along with its effect on stimulating or inhibiting ACE-2 were determined in isolated rat thoracic aorta.
resultsThe results indicated that AERV decreased the systolic, diastolic, mean, and mean arterial blood pressure in hypertensive rats. The data revealed that AERV exerted its antihypertensive effect through vasodilatory properties via an endothelium-independent pathway. Interestingly, the study demonstrated that the vasorelaxation ability of AERV might be mediated through receptor-operated calcium channels (ROCC). However, AERV extract had no effect on either stimulating or inhibiting ACE-2.
conclusionThe present study demonstrates clearly the antihypertensive and vasorelaxant activities of R. vesicarius in hypertensive rats, supporting its beneficial action as an antihypertensive agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.